Vaccinex Inc (VCNX)
5.65
+0.15
(+2.73%)
USD |
NASDAQ |
May 21, 12:17
Vaccinex Enterprise Value: 7.280M for May 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 20, 2024 | 7.280M |
| May 17, 2024 | 7.343M |
| May 16, 2024 | 7.338M |
| May 15, 2024 | 7.478M |
| May 14, 2024 | 7.296M |
| May 13, 2024 | 7.377M |
| May 10, 2024 | 7.676M |
| May 09, 2024 | 7.137M |
| May 08, 2024 | 7.596M |
| May 07, 2024 | 8.322M |
| May 06, 2024 | 7.834M |
| May 03, 2024 | 8.151M |
| May 02, 2024 | 8.357M |
| May 01, 2024 | 8.072M |
| April 30, 2024 | 7.977M |
| April 29, 2024 | 7.834M |
| April 26, 2024 | 7.802M |
| April 25, 2024 | 7.963M |
| April 24, 2024 | 6.495M |
| April 23, 2024 | 6.429M |
| April 22, 2024 | 6.392M |
| April 19, 2024 | 6.266M |
| April 18, 2024 | 6.171M |
| April 17, 2024 | 6.234M |
| April 16, 2024 | 6.107M |
| Date | Value |
|---|---|
| April 15, 2024 | 6.535M |
| April 12, 2024 | 8.230M |
| April 11, 2024 | 9.339M |
| April 10, 2024 | 9.352M |
| April 09, 2024 | 9.941M |
| April 08, 2024 | 9.704M |
| April 05, 2024 | 9.355M |
| April 04, 2024 | 9.355M |
| April 03, 2024 | 9.26M |
| April 02, 2024 | 9.169M |
| April 01, 2024 | 9.553M |
| March 28, 2024 | 9.122M |
| March 27, 2024 | 7.741M |
| March 26, 2024 | 7.865M |
| March 25, 2024 | 8.117M |
| March 22, 2024 | 8.259M |
| March 21, 2024 | 8.144M |
| March 20, 2024 | 8.248M |
| March 19, 2024 | 8.225M |
| March 18, 2024 | 8.132M |
| March 15, 2024 | 7.957M |
| March 14, 2024 | 8.354M |
| March 13, 2024 | 8.552M |
| March 12, 2024 | 8.062M |
| March 11, 2024 | 8.539M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.666M
Minimum
Sep 27 2023
174.03M
Maximum
Jul 21 2020
52.92M
Average
48.30M
Median
Enterprise Value Benchmarks
| Emergent BioSolutions Inc | 1.131B |
| Avinger Inc | 12.42M |
| RAPT Therapeutics Inc | -1.965M |
| NovaBay Pharmaceuticals Inc | 7.267M |
| Palatin Technologies Inc | 22.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.317M |
| Total Expenses (Quarterly) | 4.988M |
| EPS Diluted (Quarterly) | -3.716 |
| Earnings Yield | -1.15K% |
| Normalized Earnings Yield | -1496.64 |